- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Automatic Translation feature is available on CiNii Labs
- Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
Effect of a selective <scp>SGLT</scp>2 inhibitor, luseogliflozin, on circadian rhythm of sympathetic nervous function and locomotor activities in metabolic syndrome rats
-
- Asadur Rahman
- Department of Pharmacology Faculty of Medicine Kagawa University Kagawa Japan
-
- Yoshihide Fujisawa
- Life Science Research Center Faculty of Medicine Kagawa University Kagawa Japan
-
- Daisuke Nakano
- Department of Pharmacology Faculty of Medicine Kagawa University Kagawa Japan
-
- Hirofumi Hitomi
- Department of Pharmacology Faculty of Medicine Kagawa University Kagawa Japan
-
- Akira Nishiyama
- Department of Pharmacology Faculty of Medicine Kagawa University Kagawa Japan
Search this article
Description
<jats:title>Summary</jats:title><jats:p>Metabolic syndrome is often associated with disruption of circadian rhythm of systemic haemodynamics and cardiovascular disease. Experiments were conducted to investigate the effects of luseogliflozin, a selective <jats:styled-content style="fixed-case">SGLT</jats:styled-content>2 inhibitor, on circadian rhythm of sympathetic nervous function and locomotor activity (<jats:styled-content style="fixed-case">LA</jats:styled-content>) in metabolic syndrome rats. The difference in the low frequency component of systolic blood pressure between the dark and light period significantly increased in the luseogliflozin‐treated <jats:styled-content style="fixed-case">SHR</jats:styled-content>cp. <jats:styled-content style="fixed-case">LA</jats:styled-content> also increased in the dark period compared with the light period following luseogliflozin treatment. These data suggest that circadian rhythm of sympathetic nervous function and <jats:styled-content style="fixed-case">LA</jats:styled-content> is improved by luseogliflozin in metabolic syndrome rats, which may contribute to <jats:styled-content style="fixed-case">SGLT</jats:styled-content>2 inhibitor‐induced improvement of cardiovascular outcomes.</jats:p>
Journal
-
- Clinical and Experimental Pharmacology and Physiology
-
Clinical and Experimental Pharmacology and Physiology 44 (4), 522-525, 2017-03-27
Wiley
